OncoMatch/Clinical Trials/NCT06649851
G-CSF After Chemo-radiation in Patients With Glioblastoma
Is NCT06649851 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Granulocyte Colony Stimulating Factor (G-CSF) for mgmt-methylated glioblastoma.
Treatment: Granulocyte Colony Stimulating Factor (G-CSF) — This research study involves the study of granulocyte colony stimulating factor (G-CSF) in patients with MGMT-methylated glioblastoma multiforme (GBM) that are undergoing standard chemoradiation. The study aims to evaluate G-CSF's effects on brain health and cognitive function. The name of the study drugs involved in this study are: * G-CSF (also called Filgrastim) * Temozolomide (TMZ), a standard of care chemotherapy drug
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Biomarker criteria
Required: MGMT promoter methylation (positive)
Molecular analysis needs to confirm a positive MGMT promoter methylation status using standard institutional testing methods
Required: IDH1 wild-type
IDH wildtype
Disease stage
Required: Stage WHO GRADE 4 (WHO)
Grade: 4 (WHO)
World Health Organization (WHO) grade 4
Prior therapy
Cannot have received: cranial irradiation
Lab requirements
Blood counts
leukocytes ≥2,500/mcL; absolute neutrophil count ≥1,500/mcL; platelets ≥100,000/mcL
Kidney function
creatinine ≤ institutional ULN OR GFR ≥60 mL/min/1.73 m2 unless data exists supporting safe use at lower kidney function values, no lower than 30 mL/min/1.73 m2
Liver function
total bilirubin ≤ institutional ULN (≤3xULN for Gilbert's syndrome); AST(SGOT)/ALT(SGPT) ≤3 × institutional ULN
Participants must have adequate organ and bone marrow function (as defined below) to be able to receive standard chemoradiation therapy: * leukocytes ≥2,500/mcL * absolute neutrophil count≥1,500/mcL * platelets ≥100,000/mcL * total bilirubin≤ institutional upper limit of normal (ULN) * AST(SGOT)/ALT(SGPT)≤3 × institutional ULN creatinine≤ institutional ULN OR * glomerular filtration rate (GFR) ≥60 mL/min/1.73 m2 unless data exists supporting safe use at lower kidney function values, no lower than 30 mL/min/1.73 m2. For patients with Gilbert's syndrome, total bilirubin can be ≤ 3xULN.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Massachusetts General Hospital · Boston, Massachusetts
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify